Glofitamab,Obinutuzumab,Tocilizumab
Roche
['glofitamab', 'lymsm', 'lymphoma']
progression is uncommon in patients with relapsed/refractory large b-cell lymphoma who are in complete remission at the end of glofitamab treatment. #ash22 #lymsm #lbcl 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.